Literature DB >> 8040904

Hypertension in pregnancy.

A Anyaegbunam1, C Edwards.   

Abstract

Hypertension, which is the most common complication of pregnancy, is a leading cause of both maternal and perinatal morbidity. Advances in research related to hypertensive disorders in pregnancy have facilitated a better general understanding of the pathophysiologic processes associated with this disease. Strategies of prevention, early diagnosis, and newer treatments have contributed to a more favorable outcome for mothers and their babies. The exact cause of preeclampsia remains elusive; however, recent investigations suggest that endothelial cell injury due to free radical-mediated lipid peroxidation may be the initiator of the pathophysiologic events of preeclampsia. Future challenges in this area should include efforts to elucidate mechanisms involved in free radical cell-mediated vascular disturbances and antioxidant defenses.

Entities:  

Mesh:

Year:  1994        PMID: 8040904      PMCID: PMC2607637     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  25 in total

1.  Coagulation profile in severe preeclampsia.

Authors:  L Leduc; J M Wheeler; B Kirshon; P Mitchell; D B Cotton
Journal:  Obstet Gynecol       Date:  1992-01       Impact factor: 7.661

2.  Coagulation changes in eclampsia: their frequency and pathogenesis.

Authors:  J A Pritchard; F G Cunningham; R A Mason
Journal:  Am J Obstet Gynecol       Date:  1976-04-15       Impact factor: 8.661

Review 3.  Diazoxide.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1976-06-03       Impact factor: 91.245

4.  Platelet angiotensin II binding sites in normotensive and hypertensive women.

Authors:  P N Baker; F Broughton Pipkin; E M Symonds
Journal:  Br J Obstet Gynaecol       Date:  1991-05

Review 5.  Pregnancy and liver disease.

Authors:  M M Steven
Journal:  Gut       Date:  1981-07       Impact factor: 23.059

6.  Hypertension in pregnancy: clinical-pathological correlations and remote prognosis.

Authors:  K A Fisher; A Luger; B H Spargo; M D Lindheimer
Journal:  Medicine (Baltimore)       Date:  1981-07       Impact factor: 1.889

7.  The prevention of the maternal manifestations of pre-eclampsia by intensive antihypertensive treatment.

Authors:  S Blake; D MacDonald
Journal:  Br J Obstet Gynaecol       Date:  1991-03

Review 8.  Prevention and treatment of pregnancy-associated hypertension: what have we learned in the last 10 years?

Authors:  G Remuzzi; P Ruggenenti
Journal:  Am J Kidney Dis       Date:  1991-09       Impact factor: 8.860

9.  Preeclamptic sera stimulate increased platelet-derived growth factor mRNA and protein expression by cultured human endothelial cells.

Authors:  R N Taylor; T J Musci; G M Rodgers; J M Roberts
Journal:  Am J Reprod Immunol       Date:  1991-04       Impact factor: 3.886

10.  Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension.

Authors:  P C Rubin; L Butters; D M Clark; B Reynolds; D J Sumner; D Steedman; R A Low; J L Reid
Journal:  Lancet       Date:  1983-02-26       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.